Volrustomig — Drug Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

6 Recruiting

5 Completed trials

3 Sponsors

17 Countries

Phase III

Phase II

Phase I (Other)

Phase III: 3 Phase II: 8 Phase I/II: 1 Phase I (Other): 2

Oversight events:

11 temporary halts 1 urgent safety measure 2 corrective measures across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer stage II 1 Renal cell carcinoma 1 Adenocarcinoma gastric 1 Hepatocellular carcinoma 1 Non-small cell lung cancer metastatic 1 Non-small cell lung cancer stage IIIB 1 Gallbladder cancer 1 Non-small cell lung cancer stage IIIA 1 Colorectal cancer 1 Non-small cell lung cancer 1 Non-small cell lung cancer stage III 1 Cholangiocarcinoma 1

Sponsors using this IMP

AstraZeneca AB 12 Assistance Publique Hopitaux De Paris 1 Institut Bergonie 1

All trials

14 total

Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors Pending

2025-523947-36-00 Phase II 2 countries AstraZeneca AB
Volrustomig Priming Regimens Exploratory Phase II Platform Study Recruiting

2023-509482-20-00 Phase II 6 countries AstraZeneca AB
Master Protocol of Novel Study Interventions and Combinations in Participants with Colorectal Cancer Recruiting

2024-518469-84-00 Phase II 5 countries AstraZeneca AB
A trial to learn if volrustomig is safe and efficacious in women and young adults with locally advanced cervical cancer. Recruiting

2023-504374-38-00 Phase III 6 countries AstraZeneca AB
Master protocol of novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction … Recruiting

2024-510977-27-00 Phase II 1 country AstraZeneca AB
Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable Non-small Cell Lung Cancer Recruiting

2023-508852-21-00 Phase II 7 countries AstraZeneca AB
A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting

2023-504888-16-00 Phase I/II 5 countries AstraZeneca AB
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Phase III 9 countries AstraZeneca AB
Master Protocol of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobilia… Ended

2022-502317-29-00 Phase II 2 countries AstraZeneca AB
Phase 1b Study of Dato-DXd in Combination with Immunotherapy with or without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cance… Ended

2023-505992-54-00 Phase I (Other) 4 countries Astrazeneca AB
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in C… Ended

2023-509604-15-00 Phase I (Other) 2 countries AstraZeneca AB
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Phase III 11 countries AstraZeneca AB
Monalizumab and MEDI5752 in patients with MSI and/or dMMR metastatic cancer (MONAMI) Ended

2024-511857-23-00 Phase II 1 country Assistance Publique Hopitaux De Paris
A multicentric phase II trial evaluating volrusotmig in patients with mature tertiary lymphoid structures solid tumors. Expired

2023-503451-94-00 Phase II 1 country Institut Bergonie

Showing 1–14 of 14 trials

← All drugs A–Z